Dr. Schwartz on the Results of the PACIFIC Trial
February 19th 2018Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).
Read More
Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma
June 19th 2015Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.
Read More
The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.
Read More